TY - JOUR
T1 - Ceftobiprole medocaril
T2 - A new generation β-lactam
AU - Del Pozo, Jose L.
AU - Patel, Robin
PY - 2008/11
Y1 - 2008/11
N2 - Ceftobiprole is a novel parenteral cephalosporin with high affinity for most penicillin-binding proteins, including the mecA product penicillin-binding protein (PBP) 2a, rendering it active against methicillin-resistant staphylococci. Its in vitro activity against staphylococci and multiresistant pneumococci, combined with its Gram-negative spectrum comparable to that of other extended-spectrum cephalosporins, its stability against a wide range of β-lactamases and its pharmacokinetic and safety profile make ceftobiprole an attractive new antimicrobial agent. Because of its low water solubility, ceftobiprole is administered intravenously as a prodrug, ceftobiprole medocaril. Ceftobiprole medocaril is generally well tolerated (with the exception of a caramel-like taste disturbance). Ceftobiprole medocaril has been evaluated in two phase III clinical trials for the treatment of complicated skin infections and skin structure infections. Its broad spectrum of activity may allow ceftobiprole to be used as monotherapy for some infections where combination therapy would otherwise be required, especially regimens requiring coverage of methicillin-resistant Staphylococcus aureus (MRSA).
AB - Ceftobiprole is a novel parenteral cephalosporin with high affinity for most penicillin-binding proteins, including the mecA product penicillin-binding protein (PBP) 2a, rendering it active against methicillin-resistant staphylococci. Its in vitro activity against staphylococci and multiresistant pneumococci, combined with its Gram-negative spectrum comparable to that of other extended-spectrum cephalosporins, its stability against a wide range of β-lactamases and its pharmacokinetic and safety profile make ceftobiprole an attractive new antimicrobial agent. Because of its low water solubility, ceftobiprole is administered intravenously as a prodrug, ceftobiprole medocaril. Ceftobiprole medocaril is generally well tolerated (with the exception of a caramel-like taste disturbance). Ceftobiprole medocaril has been evaluated in two phase III clinical trials for the treatment of complicated skin infections and skin structure infections. Its broad spectrum of activity may allow ceftobiprole to be used as monotherapy for some infections where combination therapy would otherwise be required, especially regimens requiring coverage of methicillin-resistant Staphylococcus aureus (MRSA).
UR - http://www.scopus.com/inward/record.url?scp=60949093160&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=60949093160&partnerID=8YFLogxK
U2 - 10.1358/dot.2008.44.11.1308915
DO - 10.1358/dot.2008.44.11.1308915
M3 - Article
C2 - 19180259
AN - SCOPUS:60949093160
SN - 1699-3993
VL - 44
SP - 801
EP - 825
JO - Drugs of Today
JF - Drugs of Today
IS - 11
ER -